journal cover

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial

The Lancet Oncology

Nov 25, 2019

Aung NaingNizar M Tannir

Get paper from

Abstract

IL-10 has anti-inflammatory and CD8+ T-cell stimulating activities. Pegilodecakin (pegylated IL-10) is a first-in-class, long-acting IL-10 receptor agonist that induces oligoclonal T-cell expansion and has single-agent activity in advanced solid tumours. We assessed the safety and activ...read more

Mentioned in this Paper

Anemia
Malignant Neoplasm of Urinary Bladder
Malignant Neoplasms
Non-Small Cell Lung Carcinoma
Renal Cell Carcinoma
Cell Growth
Clinical Trials
Hypertriglyceridemia
Melanoma
Neoplasms
38
11
19
Paper Details
References
  • References
  • Citations1
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.

Similar Papers Found In These Feeds

Kidney Carcinoma

Kidney or renal carcinoma is a malignant tumor that start in the kidney. Renal cell carcinoma and transitional cell carcinoma are the two most common types of kidney cancer. Several factors, both genetic and environmental, have been implicated in this cancer. Here is the latest research.

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

Immuno-Oncology

Immuno-oncology (or cancer immunotherapy) is the artificial stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight cancer. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules. Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill. Discover the latest research on immuno-oncology here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Skin Cutaneous Melanoma

Cutaneous melanoma is a cancer of the pigment-producing cells known as melanocytes. While it has a 98 percent five-year survival rate when caught early, thousands of deaths are attributed to this cancer each year. Here is the latest research.

Cross-Priming

Cross-priming is the process whereby professional APC, mainly dendritic cells, prime t-cells by presenting antigens processed from proteins of other cells such as tumor cells or virus-infected cells. Discover the latest research on cross-priming here.

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms are the most common urinary system malignancy. Signs and symptoms of bladder cancer include hematuria, pelvic pain, and painful urination. Discover the latest research on bladder cancer here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Renal Cell Carcinoma

Renal cell carcinoma, the most common type of kidney cancer, originates in the lining of the proximal convoluted tubule. Both genetic and lifestyle factors have been implicated with increased risk of developing this cancer. Here is the latest research on renal cell carcinoma.

© 2019 Meta ULC. All rights reserved

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial

The Lancet Oncology

Nov 25, 2019

Aung NaingNizar M Tannir

PMID: 31563517

DOI: 10.1016/s1470-2045(19)30514-5

Abstract

IL-10 has anti-inflammatory and CD8+ T-cell stimulating activities. Pegilodecakin (pegylated IL-10) is a first-in-class, long-acting IL-10 receptor agonist that induces oligoclonal T-cell expansion and has single-agent activity in advanced solid tumours. We assessed the safety and activ...read more

Mentioned in this Paper

Anemia
Malignant Neoplasm of Urinary Bladder
Malignant Neoplasms
Non-Small Cell Lung Carcinoma
Renal Cell Carcinoma
38
11
19

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References
  • Citations1
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.

Get paper from

/papers/pegilodecakin-combined-with-pembrolizumab-or/31563517